Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2.

K. R. Meehan, U. N. Verma, C. Rajogopal, R. Cahill, S. Frankel, A. Mazumder

Research output: Contribution to journalReview article

17 Scopus citations

Abstract

Interleukin 2 (IL-2) stimulates the proliferation of T-cells both in vitro and in vivo. When murine or human peripheral blood (PB) or bone marrow (BM) mononuclear cells are incubated with IL-2 in vitro for 24 hours, cytotoxic T-cells are generated. If these activated cells are infused into mice, the enhanced cytotoxicity continues if low dose IL-2 is administered. This combination of administering activated cells with the subsequent low dose IL-2 infusion results in enhanced tumor cell destruction and improved survival rates in mice with acute myeloid leukemia. The encouraging results of these laboratory experiments prompted the initiation of phase I clinical trials in patients with refractory/relapsed hematologic malignancies and patients with breast cancer (Stages II-IV). Results from these trials demonstrate that stem cell transplantation with IL-2 activated stem cells (either PB or BM) with or without parenteral administration of IL-2 results in hematopoietic reconstitution with mild-to-moderate toxicities. This regimen also generates cutaneous and visceral autologous graft versus host disease (AuGVHD). The majority of our patients with relapsed/refractory hematologic malignancies or breast cancer developed either clinical and/or histological evidence of AuGVHD. Further studies are being conducted to determine if patients who develop AuGVHD experience improved disease-free survival from a possible autologous graft versus tumor (GVT) effect. Current laboratory evaluations include the elucidation of the pathogenesis of AuGVHD and molecular evaluation of the purging efficacy of IL-2.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalThe Journal of infusional chemotherapy
Volume6
Issue number1
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Microbiology

Fingerprint Dive into the research topics of 'Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2.'. Together they form a unique fingerprint.

  • Cite this

    Meehan, K. R., Verma, U. N., Rajogopal, C., Cahill, R., Frankel, S., & Mazumder, A. (1996). Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. The Journal of infusional chemotherapy, 6(1), 28-32.